These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35412210)

  • 1. ASO Author Reflections: Neoadjuvant Systemic Chemotherapy in Isolated Resectable Colorectal Peritoneal Metastases: Ready for Standard of Care?
    Flood MP; Ramsay R; Michael M; Heriot AG
    Ann Surg Oncol; 2022 Oct; 29(11):6632-6633. PubMed ID: 35412210
    [No Abstract]   [Full Text] [Related]  

  • 2. ASO Author Reflections: Which is the Optimal Preoperative Systemic Chemotherapy Regimen for Patients with Peritoneal Metastases from Colorectal Cancer?
    Kepenekian V; Kefleyesus A; Passot G; Rousset P; Benzerdjeb N; You B; Peron J; Glehen O
    Ann Surg Oncol; 2023 Jun; 30(6):3316-3317. PubMed ID: 36752969
    [No Abstract]   [Full Text] [Related]  

  • 3. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
    Rovers KP; Bakkers C; Simkens GAAM; Burger JWA; Nienhuijs SW; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; Ayez N; de Boer NL; van Meerten E; Tuynman JB; Kusters M; Sluiter NR; Verheul HMW; van der Vliet HJ; Wiezer MJ; Boerma D; Wassenaar ECE; Los M; Hunting CB; Aalbers AGJ; Kok NFM; Kuhlmann KFD; Boot H; Chalabi M; Kruijff S; Been LB; van Ginkel RJ; de Groot DJA; Fehrmann RSN; de Wilt JHW; Bremers AJA; de Reuver PR; Radema SA; Herbschleb KH; van Grevenstein WMU; Witkamp AJ; Koopman M; Haj Mohammad N; van Duyn EB; Mastboom WJB; Mekenkamp LJM; Nederend J; Lahaye MJ; Snaebjornsson P; Verhoef C; van Laarhoven HWM; Zwinderman AH; Bouma JM; Kranenburg O; van 't Erve I; Fijneman RJA; Dijkgraaf MGW; Hemmer PHJ; Punt CJA; Tanis PJ; de Hingh IHJT; ;
    BMC Cancer; 2019 Apr; 19(1):390. PubMed ID: 31023318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASO Author Reflections: If Once Is Good, Is Twice Just as Good? A critical evaluation of Repeat CRS-HIPEC for Colorectal Peritoneal Metastases.
    Laks S; Adileh M; Ben-Yaacov A; Nissan A
    Ann Surg Oncol; 2021 Sep; 28(9):5339-5340. PubMed ID: 33604829
    [No Abstract]   [Full Text] [Related]  

  • 5. ASO Author Reflections: Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Tonello M; Sommariva A
    Ann Surg Oncol; 2022 Jun; 29(6):3418-3419. PubMed ID: 34743279
    [No Abstract]   [Full Text] [Related]  

  • 6. ASO Author Reflections: Pathologic Response Ratio (PRR) in CRS and HIPEC for Peritoneal Metastasis from Colorectal Cancer.
    Mor E; Laks S; Nissan A; Adileh M
    Ann Surg Oncol; 2021 Dec; 28(13):9148-9149. PubMed ID: 34180017
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Comments on "The Impact of Neoadjuvant Chemotherapy on the Surgical Management of Colorectal Peritoneal Metastases: A Systematic Review and Meta-analysis".
    Flood MP; Kong JCH; Heriot AG
    Ann Surg Oncol; 2022 Nov; 29(12):7935-7936. PubMed ID: 36103013
    [No Abstract]   [Full Text] [Related]  

  • 8. Comments on "The Impact of Neoadjuvant Chemotherapy on the Surgical Management of Colorectal Peritoneal Metastases: A Systematic Review and Meta-analysis".
    Liberale G; Moreau M; Repullo D
    Ann Surg Oncol; 2022 Nov; 29(12):7933-7934. PubMed ID: 36100833
    [No Abstract]   [Full Text] [Related]  

  • 9. Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
    Rovers KP; Bakkers C; Nienhuijs SW; Burger JWA; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; van Meerten E; Tuynman JB; Kusters M; Versteeg KS; Aalbers AGJ; Kok NFM; Buffart TE; Wiezer MJ; Boerma D; Los M; de Reuver PR; Bremers AJA; Verheul HMW; Kruijff S; de Groot DJA; Witkamp AJ; van Grevenstein WMU; Koopman M; Nederend J; Lahaye MJ; Kranenburg O; Fijneman RJA; van 't Erve I; Snaebjornsson P; Hemmer PHJ; Dijkgraaf MGW; Punt CJA; Tanis PJ; de Hingh IHJT;
    JAMA Surg; 2021 Aug; 156(8):710-720. PubMed ID: 34009291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASO Author Reflections: Toward Improved Selection of Patients for Cytoreduction and HIPEC: Identification of Prognostic Factors for Patients with Colorectal Peritoneal Metastases.
    Sluiter NR; Tuynman JB
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):840-841. PubMed ID: 30302638
    [No Abstract]   [Full Text] [Related]  

  • 11. ASO Author Reflections: Combination Intra-Peritoneal and Systemic Chemotherapy for Gastric Cancer with Peritoneal Metastases.
    Chia DKA; Ang JJ; Sundar R; Kim G; Shabbir A; So JBY; Yong WP
    Ann Surg Oncol; 2022 Dec; 29(13):8606-8607. PubMed ID: 36192514
    [No Abstract]   [Full Text] [Related]  

  • 12. ASO Author Reflections: Potential Therapeutic Implications and Prediction of Pathological Complete Response to Systemic Chemotherapy in Colorectal Peritoneal Metastases.
    Bhatt A; Képénékian V; Benzerdjeb N; Glehen O
    Ann Surg Oncol; 2021 Jul; 28(7):3850-3851. PubMed ID: 33211229
    [No Abstract]   [Full Text] [Related]  

  • 13. ASO Author Reflections: What is the Best Therapeutic Strategy for Patients with Limited Synchronous Peritoneal Metastases of Colorectal Cancer?
    Mariani A; Goere D
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):818. PubMed ID: 31667730
    [No Abstract]   [Full Text] [Related]  

  • 14. Diagnostic performance of MRI for staging peritoneal metastases in patients with colorectal cancer after neoadjuvant chemotherapy.
    Rijsemus CJV; Kok NFM; Aalbers AGJ; Buffart TE; Fijneman RJA; Snaebjornsson P; Engbersen MP; Lambregts DMJ; Beets-Tan RGH; Lahaye MJ
    Eur J Radiol; 2022 Apr; 149():110225. PubMed ID: 35255321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASO Author Reflections: Fragmented Care in Patients with Peritoneal Metastases.
    Vierra M; Bansal VV; Shergill A; Turaga KK; Eng OS
    Ann Surg Oncol; 2024 Jan; 31(1):655-656. PubMed ID: 37803088
    [No Abstract]   [Full Text] [Related]  

  • 16. Perioperative systemic therapy for resectable colorectal peritoneal metastases: Sufficient evidence for its widespread use? A critical systematic review.
    Rovers KP; Simkens GA; Punt CJ; van Dieren S; Tanis PJ; de Hingh IH
    Crit Rev Oncol Hematol; 2017 Jun; 114():53-62. PubMed ID: 28477747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASO Author Reflections: Is There Still a Role for Intraperitoneal Oxaliplatin for Colorectal Peritoneal Metastases?
    Taibi A; Hübner M; Eveno C; Dumont F; Glehen O; Sgarbura O
    Ann Surg Oncol; 2022 Aug; 29(8):5252-5253. PubMed ID: 35355127
    [No Abstract]   [Full Text] [Related]  

  • 18. ASO Author Reflections: Cytoreductive Surgery for Colorectal Peritoneal Metastases-Is It Time to Audit Our Results?
    García-Fadrique A
    Ann Surg Oncol; 2022 Jan; 29(1):203-204. PubMed ID: 34435299
    [No Abstract]   [Full Text] [Related]  

  • 19. ASO Author Reflections: The Timing of Onset of Peritoneal Metastases from Colorectal Carcinoma Is Not an Independent Predictor of Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Dietz MV; Madsen EVE
    Ann Surg Oncol; 2022 Oct; 29(11):6577-6578. PubMed ID: 35486267
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of preoperative chemotherapy on the histological response of patients with peritoneal metastases from colorectal cancer according to peritoneal regression grading score (PRGS) and TRG.
    Taibi A; Lo Dico R; Kaci R; Naneix AL; Mathonnet M; Pocard M
    Surg Oncol; 2020 Jun; 33():158-163. PubMed ID: 32561082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.